Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

Ishan Roy, Gordon Smilnak, Madelyn Burkart, Elizabeth Hamilton, Katherine Thorp, Sarah Miyata, Shuo Ma, Barbara Pro, Jane Winter, Leo Gordon, Reem Karmali*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Cachexia is a muscle-wasting syndrome that is known to impact the clinical course of several cancer populations but has not been specifically investigated in patients receiving chimeric antigen receptor T (CAR-T) cell therapy. In this study, we investigated the relationship between cachexia markers and several cancer and functional outcomes in a pilot population of aggressive B-cell non-Hodgkin lymphoma patients receiving CAR-T. We found that the prognostic nutritional index was linked to progression-free survival, overall survival, and disability-free survival, while several additional weight and serum-based markers of cachexia were also associated with negative outcomes. These data prompt further investigation of cachexia markers in populations receiving CAR-T cell therapy.

Original languageEnglish (US)
Pages (from-to)71-75
Number of pages5
JournalBritish Journal of Haematology
Volume197
Issue number1
DOIs
StatePublished - Apr 2022

Keywords

  • immunotherapy
  • metabolism
  • non-Hodgkin lymphoma
  • quality of life
  • risk factors

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Cite this